Alexza Pharmaceuticals To Present AZ-004 Phase 2a Clinical Data At The American Psychiatric Association Annual Meeting
May 15th 2008Drug InformationSchizophrenia
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present at the 161st American Psychiatric Association annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
